A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Inhibition of tumor growth factor-β (TGF-β) receptor type I potentiated the activity of sorafenib in preclinical models of hepatocellular carcinoma (HCC). Galunisertib is a small-molecule selective inhibitor of TGF-β1 receptor type I, which demonstrated activity in a phase 2 trial as second-line HCC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Transl Gastroenterol
Main Authors: Kelley, R.K., Gane, E., Assenat, E., Siebler, J., Galle, P.R., Merle, P., Hourmand, I.O., Cleverly, A., Zhao, Y., Gueorguieva, I., Lahn, M., Faivre, S., Benhadji, K.A., Giannelli, G.
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6708671/
https://ncbi.nlm.nih.gov/pubmed/31295152
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14309/ctg.0000000000000056
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados